Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash & Current Investments (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Cash & Current Investments for 14 consecutive years, with $172.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 36.62% to $172.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $172.1 million through Dec 2025, up 36.62% year-over-year, with the annual reading at $172.1 million for FY2025, 36.62% up from the prior year.
  • Cash & Current Investments hit $172.1 million in Q4 2025 for Coherus Oncology, down from $191.7 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $468.7 million in Q3 2021 to a low of $72.9 million in Q2 2023.
  • Historically, Cash & Current Investments has averaged $229.8 million across 5 years, with a median of $191.7 million in 2022.
  • Biggest five-year swings in Cash & Current Investments: tumbled 73.53% in 2023 and later surged 118.35% in 2024.
  • Year by year, Cash & Current Investments stood at $417.2 million in 2021, then plummeted by 54.05% to $191.7 million in 2022, then plummeted by 38.57% to $117.7 million in 2023, then rose by 7.0% to $126.0 million in 2024, then skyrocketed by 36.62% to $172.1 million in 2025.
  • Business Quant data shows Cash & Current Investments for CHRS at $172.1 million in Q4 2025, $191.7 million in Q3 2025, and $237.6 million in Q2 2025.